Bio-Path Holdings Provides 2024 Clinical and Operational Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. NEST:IN
10. AA

Go back to Bio-Path Holdings Provides 2024 Clinical and Operational Update

Roth/MKM Reiterates $40 PT on Bio-Path Holdings (BPTH): 'Business Update Includes Developing Prexigebersen For Obesity'

April 2, 2024 10:50 AM EDT

Roth/MKM analyst Philip Shen reiterated a Buy rating and $40.00 price target on Bio-Path Holdings (NASDAQ: BPTH).

The analyst comments "BPTH outlined its business plan most notably by adding obesity and obesityrelated cancers to its prexigebersen development plans, a drug currently in Phase 2 development in AML. BPTH is... More